Lilly Says LY4170156 Shows Promising Safety And Anti-Tumor Activity In Phase 1 Ovarian Cancer Trial

Eli Lilly (LLY) announced positive Phase 1 data for its next-generation folate receptor alpha (FRa) antibody-drug conjugate (ADC), LY4170156, in heavily pre-treated platinum-resistant ovarian cancer patients, including those previously treated with mirvetuximab soravtansine. The trial demonstrated an encouraging safety profile and a preliminary overall objective response rate (ORR) of 55% at the potential recommended Phase 2 dose of 4 mg/kg across various FRa expression levels, prompting Lilly to plan for registrational Phase 3 trials to potentially expand the number of ovarian cancer patients who could benefit from a FRa ADC.

Analysis

Eli Lilly and Co. (LLY) has announced encouraging new Phase 1 data for its investigational next-generation folate receptor alpha (FRa) antibody-drug conjugate (ADC), LY4170156, demonstrating a positive safety profile and notable anti-tumor activity in heavily pre-treated platinum-resistant ovarian cancer. The study, which enrolled 95 participants as of the March 9 data cutoff, observed a preliminary overall objective response rate (ORR) of 55% at the potential recommended Phase 2 dose of 4 mg/kg, across various FRa expression levels. Significantly, these results include patients who had received a median of five prior systemic regimens and, critically, 15% who were previously treated with mirvetuximab soravtansine, another FRa ADC, suggesting LY4170156 could offer a new therapeutic option for a challenging patient population. LY4170156, composed of an Fc-silent, FRa specific humanized monoclonal antibody linked to the topoisomerase I inhibitor exatecan, targets FRa, a glycoprotein overexpressed in multiple solid tumors. Lilly's Chief Medical Officer, David Hyman, confirmed plans to rapidly advance LY4170156 into registrational Phase 3 clinical trials, aiming to expand treatment options for ovarian cancer. Eli Lilly shares were trading at $738.63, reflecting a minor increase of 0.10% on the NYSE following the announcement, which carries a "strongly positive" sentiment for the company.

Key Decisions for Investors

• Investors should closely monitor Eli Lilly's progress in advancing LY4170156 to Phase 3 trials, as successful development could significantly enhance its oncology pipeline and address a key unmet need in ovarian cancer.
• The preliminary 55% ORR in a heavily pre-treated population, including patients previously exposed to another FRa ADC, indicates potential for LY4170156 as a differentiated therapy; upcoming presentations at ASCO and further data will be crucial for assessing its competitive standing.
• Considering the positive early-stage data and Lilly's commitment to accelerated development, the long-term commercial potential of LY4170156 warrants attention, while also acknowledging the inherent risks and timelines associated with late-stage clinical trials and regulatory approvals.